Key facts
- Remediiate’s last known valuation is $4.0M (Mar 2025).
- It has raised $1.2M.
- Notable investors include NZIP Acceleration, UK Department for Energy Security and Net Zero.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Remediiate
- ·The full record, as it builds
Funding rounds
No funding rounds for Remediiate are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Remediiate
Operator of biotechnology carbon capture technology intended to convert carbon dioxide emissions into biomass using microalgae cultivation. The company offers microalgae cultivation systems, carbon dioxide conversion processes, biomass production, biochemical extraction, and carbon capture utilization, enabling industrial emitters and feed producers to access systems for transforming emissions into feed and material inputs.
- Sector
- Energy
- HQ
- Swansea, United Kingdom
- Founded
- 2017
- Employees
- 9
- Website
- remediiate.com/
- Ownership
- Privately Held (backing)
Remediiate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Remediiate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Remediiate in its N-PORT filings yet. We sweep new filings monthly.